The Drug Enforcement Administration (DEA) is currently considering a proposal to reschedule cannabis, and public response has been overwhelmingly positive. Within the first week, the agency received more than 7,000 comments. As the public comment period continues until July 22, the total number of submissions has already surpassed 11,000.
Breakdown of Public Comments
Recent analysis by cannabis data firm Headset indicates that 97% of the comments submitted through May 29 favor the proposed regulation. The highest level of support was recorded on May 23, with 2,657 comments in approval. Opposition has remained minimal throughout the period, and the trend of overwhelming support continues.
DEA’s Proposal and HHS Recommendation
The DEA’s notice of proposed rulemaking is based on a recommendation from the Department of Health and Human Services (HHS). The HHS suggests that cannabis has a lower potential for abuse compared to Schedule I and II substances, has accepted medical uses, and poses limited risks of physical or psychological dependence. The recommendation also recognizes the medical use of cannabis for treating conditions such as anorexia, nausea, vomiting, and pain.
Public Perspectives
The comments submitted to the Federal Register reflect diverse viewpoints. The first official comment came from a USMC veteran with PTSD and chronic pain, expressing gratitude for the government’s leadership and highlighting the benefits of rescheduling cannabis for millions of Americans.
“The cannabis plant saved my life,” wrote the anonymous commenter. “I am now pain-free, have full mobility, and am in a strong positive mental state since being in Nevada’s State Medical Program since 2017. With Blessing of Love and Respect to all those serving the USA. God Bless America.”
Another commenter, an autistic adult, shared how current regulations hinder access to beneficial treatments and described their personal experience using CBD oil to manage anxiety, behavioral issues, and sleep problems.
Opponents of the change cited concerns about public health, the lack of research supporting high-THC products for medical purposes, and potential risks to young people. Some questioned whether botanical cannabis meets the criteria for accepted medical use and raised concerns about associations with psychosis and other mental health issues.
Calls for Further Action
Some commenters believe that rescheduling does not go far enough. “Rescheduling cannabis is a step in the right direction, but frankly it should be descheduled entirely,” wrote one individual, a sentiment echoed throughout many submissions.
“Do my thoughts change anything? Nope,” the commenter added. “Will anyone care I shared this opinion? Probably not, but deschedule and legalize the damn plant.”
Broader Public Support
The overwhelming public support for rescheduling cannabis is mirrored in broader public opinion. A January 2024 Pew Research study found that 88% of U.S. adults support the legalization of marijuana for either medical or recreational use.
Next Steps
The public comment period will remain open until July 22. Afterward, the DEA will review all submissions and may grant an administrative hearing to gather more evidence about the proposal. The outcome could significantly impact the future of cannabis regulation in the United States.
OG source